

cultural, religious, or socioeconomic status.

Documentation must be included in the nomination to indicate that the nominated individual is willing to serve as a member of SACHRP. Individuals who are selected to be considered for appointment will be required to provide detailed information regarding their financial holdings, consultancies, and research grants or contracts. Disclosure of this information is necessary in order to determine if the selected candidate is involved in any activity that may pose a potential conflict with the official duties to be performed as a member of SACHRP.

Dated: October 31, 2007.

**Ivor A. Pritchard,**

*Acting Director, Office for Human Research Protections, Acting Executive Secretary, Secretary's Advisory Committee on Human Research Protections.*

[FR Doc. E7-21824 Filed 11-6-07; 8:45 am]

**BILLING CODE 4150-36-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Meeting of the Advisory Committee on Minority Health**

**AGENCY:** Department of Health and Human Services, Office of the Secretary, Office of Public Health and Science, Office of Minority Health.

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (DHHS) is hereby giving notice that the Advisory Committee on Minority Health (ACMH) will hold a meeting. This meeting is open to the public. Preregistration is required for both public attendance and comment. Any individual who wishes to attend the meeting and/or participate in the public comment session should e-mail [acmh@osophs.dhhs.gov](mailto:acmh@osophs.dhhs.gov).

**DATES:** The meeting will be held on November 27, 2007, from 9 a.m. to 4 p.m.

**ADDRESSES:** The meeting will be held at the DoubleTree Hotel, Terrace Ballroom, 1515 Rhode Island Ave., NW., Washington, DC 20005. The meeting is accessible from the Dupont Circle and McPherson Square Metro Stations. From the Dupont Circle Metro Station meeting participants may walk 2 blocks south on Connecticut Avenue, turn left on Rhode Island Avenue for approximately 5 blocks. The DoubleTree is on the left after Logan Circle. From the McPherson Square Metro Station meeting

participants may walk 5 blocks north on 14th Street, turn right on to Rhode Island Avenue for approximately 2 blocks. The DoubleTree will be on the left after Logan Circle.

**FOR FURTHER INFORMATION AND**

**REGISTRATION CONTACT:** Ms. Monica A. Baltimore, Tower Building, 1101 Wootton Parkway, Suite 600, Rockville, Maryland 20852; phone: (240) 453-2882; fax: (240) 453-2883.

**SUPPLEMENTARY INFORMATION:**

In accordance with Public Law 105-392, the ACMH was established to provide advice to the Deputy Assistant Secretary for Minority Health in improving the health of each racial and ethnic minority group and on the development of goals and specific program activities of the Office of Minority Health.

Topics to be discussed during this meeting will include Integrating Racially and Ethnically Diverse Communities into Emergency Preparedness and other strategies to improve the health of racial and ethnic minority populations through the development of health policies and programs that will help eliminate health disparities, as well as other related issues.

Public attendance at the meeting is limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person at least fourteen business days prior to the meeting. Members of the public will have an opportunity to provide comments at the meeting. Public comments will be limited to five minutes per speaker. Individuals who would like to submit written statements should mail or fax their comments to the Office of Minority Health at least five business days prior to the meeting. Any members of the public who wish to have printed material distributed to ACMH committee members should submit their materials to Garth N. Graham, M.D., M.P.H., Executive Secretary, ACMH, Tower Building, 1101 Wootton Parkway, Suite 600, Rockville, Maryland 20852, prior to close of business November 23, 2007.

Dated: October 30, 2007.

**Garth N. Graham,**

*Deputy Assistant Secretary for Minority Health.*

[FR Doc. E7-21822 Filed 11-6-07; 8:45 am]

**BILLING CODE 4150-29-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[60 Day-07-07BS]

**Proposed Data Collections Submitted for Public Comment and Recommendations; Notice**

This 60 Day **Federal Register** Notice published on September 27, 2007 (72 FR 54915-54916) has been inadvertently republished. This is a duplicate document of the previous FRN that was published on October 27, 2006. Therefore, we would like to retract it.

**Maryam I. Daneshvar,**

*Acting Reports Clearance Officer, Centers for Disease Control and Prevention.*

[FR Doc. E7-21864 Filed 11-6-07; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): State Based Occupational Safety and Health Surveillance Review, Program Announcement (PA) PAR04-106**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

*Time and Date:* 8 a.m.-5 p.m., November 30, 2007 (Closed).

*Place:* Renaissance Hotel, 6th Avenue, Pittsburgh, PA 15222.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters To Be Discussed:* The meeting will include the review, discussion, and evaluation of "State Based Occupational Safety and Health Surveillance Review, PA PAR04-106.

*For Further Information Contact:* Stephen Olenchock, Ph.D., Scientific Review Administrator, Office of Extramural Coordination and Special Projects, National Institute for Occupational Safety and Health, CDC, 1095 Willowdale Road, Morgantown, WV 26505, Telephone (304) 285-6271.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: October 29, 2007.

**Elaine L. Baker,**

*Director, Management Analysis and Services  
Office, Centers for Disease Control and  
Prevention.*

[FR Doc. E7-21842 Filed 11-6-07; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 2007N-0427]

**Lederle Laboratories et al.; Withdrawal  
of Approval of 73 New Drug  
Applications and 62 Abbreviated New  
Drug Applications**

**AGENCY:** Food and Drug Administration,  
HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 73 new drug applications (NDAs) and 62 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

**EFFECTIVE DATE:** December 7, 2007.

**FOR FURTHER INFORMATION CONTACT:**

Florine P. Purdie, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

**SUPPLEMENTARY INFORMATION:** The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their requests, waived their opportunity for a hearing.

| Application No. | Drug  | Applicant   |
|-----------------|---|---|
| NDA 6-459       | Hetrazan (diethylcarbamazine citrate) Tablets and Syrup             | Lederle Laboratories, c/o Wyeth Pharmaceuticals, Inc., P.O. Box 8299, Philadelphia, PA 19101-8299                   |
| NDA 6-799       | Rubramin and Rubramin PC (cyanocobalamin injection USP)             | Bristol-Myers Squibb Co., P.O. Box 4000, Princeton, NJ 08543-4000   |
| NDA 7-517       | Tapazole (methimazole tablets USP), 5 milligrams (mg) and 10 mg     | King Pharmaceuticals, Inc., 501 Fifth St., Bristol, TN 37620  |
| NDA 7-942       | Sus-Phrine (epinephrine) Injection                                  | Forest Laboratories, Inc., Harborside Financial Center, Plaza Three, suite 602, Jersey City, NJ 07311               |
| NDA 9-319       | Ambenyl Expectorant and Ambenyl Cough Syrup                         | Do.   |
| NDA 10-533      | PBZ SR (tripelennamine HCl USP) Extended-Release Tablets            | Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07936-1080                                       |
| NDA 10-744      | Darbid (isopropamide iodide) Tablets                                | SmithKline Beecham Corp., d/b/a/ GlaxoSmith Kline, P.O. Box 13398, Five Moore Dr., Research Triangle Park, NC 27709 |
| NDA 10-909      | Miradon (anisindione) Tablets                                       | Schering Corp., 2000 Galloping Hill Rd., Kenilworth, NJ 07033   |
| NDA 11-213      | Trilafon (perphenazine) Injection, 5 mg/milliliter (mL)             | Do.   |
| NDA 11-283      | Kenacort (tramcinolone) Tablets                                     | Bristol-Myers Squibb Co.  |
| NDA 11-808      | Mellaril (thioridazine HCl) Tablets                                 | Novartis Pharmaceuticals Corp.  |
| NDA 12-145      | Prolixin (fluphenazine HCl) Elixir, 0.5 mg/mL                       | Apothecon, c/o Bristol-Myers Squibb Co., P.O. Box 4500, Princeton, NJ 08543-4500                                    |
| NDA 12-313      | BIO-CLEAR (dibenzothiofene) Cream                                   | Helena Rubinstein, 202 Rodney Bldg., 3411 Silverside Rd., Wilmington, DE 19810                                      |
| NDA 12-665      | Velban (vinblastine sulfate) for Injection                          | Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285   |
| NDA 12-678      | Tolbutamide Tablets   | Sandoz Inc., 227-15 North Conduit Ave., Laurelton, NY 11413   |
| NDA 12-796      | Quinidex Extentabs (quinidine sulfate extended-release tablets USP) | Wyeth Pharmaceuticals, Inc.   |
| NDA 14-103      | Oncovin (vincristine sulfate) Injection                             | Eli Lilly and Co.   |
| NDA 14-242      | Dexacort (dexamethasone sodium phosphate) Turbinaire                | UCB, 755 Jefferson Rd., Rochester, NY 14623   |